RT Journal Article
SR Electronic
T1 ACE gene variants rise the risk of severe COVID-19 in patients with hypertension, dyslipidemia or diabetes. A pilot study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.24.21253576
DO 10.1101/2021.03.24.21253576
A1 Íñiguez, María
A1 Pérez-Matute, Patricia
A1 Villoslada-Blanco, Pablo
A1 Recio-Fernandez, Emma
A1 Ezquerro-Pérez, Diana
A1 Alba, Jorge
A1 Ferreira-Laso, M. Lourdes
A1 Oteo, José A.
YR 2021
UL http://medrxiv.org/content/early/2021/03/26/2021.03.24.21253576.abstract
AB Coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection continues to scale and threaten human health and public safety. It is essential to identify those risk factors that lead to a poor prognosis of the disease. A predisposing host genetic background could be one of these factors that explain the interindividual variability to COVID-19 severity. Thus, we have studied whether the rs4341 and rs4343 polymorphisms of the angiotensin converting enzyme (ACE) gene, key regulator of the renin-aldosterone-angiotensin system (RAAS), could explain the different outcomes of 128 COVID-19 patients with diverse degree of severity (33 asymptomatic or mildly asymptomatic, 66 hospitalized in the general ward, and 29 admitted to the ICU). We found that G allele of rs4341 and rs4343 was associated with severe COVID-19 in hypertensive patients, independently of gender (p<0.05). G-carrier genotypes of both polymorphisms were also associated with higher mortality (p< 0.05) and higher severity of COVID-19 in dyslipidemic (p<0.05) and type 2 diabetic patients (p< 0.01).In conclusion, our preliminary study suggests that the G-containing genotypes of rs4341 and rs4343 confer an additional risk of adverse COVID-19 prognosis. Thus, rs4341 and rs4343 polymorphisms of ACE could be predictive markers of severity of COVID-19 in those patients with hypertension, dyslipidemia or diabetes. The knowledge of these genetic data could contribute to precision management of SARS-CoV-2 infected patients when admitted to hospital.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by an independent ethical committee for clinical research (Comite de Etica de Investigacion con medicamentos de La Rioja, CEImLAR, reference number PI-412). All patients or their representatives/relatives gave their consent to participate in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.COVID-19(coronavirus disease 19)SARS-CoV-2(severe acute respiratory syndrome coronavirus 2)ACE(angiotensin converting enzyme)RAAS(renin-aldosterone-angiotensin system)ICU(intensive care unit)ACE2(angiotensin-converting enzyme-2)Ang I(angiotensin I)Ang II(angiotensin II)AT1R(angiotensin II type 1 receptor)